Breaks Categories: News

ThursdayMay 16, 2024 1:33 pm

BioMedNewsBreaks — HealthLynked Corp. (HLYK) Releases Q1 2024 Financial Results

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced its financial results for the first quarter ended March 31, 2024. During the quarter, the company’s revenue reached $1.0 million, an 8% increase compared to the fourth quarter of 2023, underscoring HealthLynked’s resilience and adaptability in managing transitions while maintaining operational efficiency. The announcement noted HealthLynked’s continued strategic focus on cost control, which saw the company reduce operating expenses in the Health Services Division by 33%, SG&A expenses by 9%, and overall operating expenses by 22% in Q1 2024 compared to Q1 2023. The company reported a net loss from…

Continue Reading

ThursdayMay 16, 2024 1:18 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Names Seasoned Business Leader to Board of Directors

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical solutions, has announced a new member of its board of directors. According to the announcement, Sergei Glinka, a seasoned and highly respected business executive, will serve on the board. An Estonian citizen, Glinka has served in several executive and board roles positions in large European companies, including Automecanica Skb Property Srl., GST Investments OU and TG Biochemicals Ltd. Glinka’s expertise will support and facilitate new licensing and networking opportunities for Nutriband throughout Europe as the company works to expand its AVERSA(TM) technology, which is patented in 45 countries. The announcement noted that…

Continue Reading

ThursdayMay 16, 2024 1:02 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases FY 2023 Financial Results, Provides Business Update

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting its full-year financial results for 2023 along with a company update. Highlights of the report included news that, in the first four months of 2024, the company has received CDMO work orders valued at approximately $500,000, with current guidance for this year of approximately $1.25 million in expected revenues. The report also noted that the company is “aggressively advancing” its NanoAb preclinical development, with promising results obtained in a…

Continue Reading

WednesdayMay 15, 2024 1:54 pm

BioMedNewsBreaks — Sigyn Therapeutics Inc. (SIGY) Announces Q1 2024 Financial Results

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, today announced financial results for the first quarter ended March 31, 2024. During the quarter, the company reported a loss from operations of $629,972, as compared to an operating loss of $521,258 for the comparable period in 2023. Sigyn Therapeutics’ net loss for Q1 2024 was $758,088 or $0.62 per share, as compared to a net loss of $1,341,036, or $1.39 per share, during Q1 2023. During the first quarter, SIGY completed a 1-for-40 reverse split of its common stock. As a result, 1,224,827 shares of company’s common stock are currently…

Continue Reading

WednesdayMay 15, 2024 1:37 pm

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Announces Record Consolidated Q1 2024 Revenues, Improved Quarterly Margins

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced record financial results for the first fiscal quarter ended March 31, 2024, which includes the consolidation of the operations of its e-commerce business with the results of its healthcare operations, Progressive Care Inc. (OTCQB: RXMD). “First quarter results continued to demonstrate the fundamental strength of NextPlat’s focus on the large healthcare services and global e-commerce technology markets and further demonstrates our team execution against its global growth plans,” said Charles M. Fernandez, executive chairman and CEO of NextPlat Corp. “Throughout the remainder of 2024, we are committed to maximizing and…

Continue Reading

WednesdayMay 15, 2024 1:28 pm

BioMedNewsBreaks — PaxMedica Inc. (PXMD) Appeals NASDAQ Delisting Decision, Prepares for June FDA Meeting

  PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has filed a formal notice of appeal with the NASDAQ Office of Appeals and Review; the company is appealing to reverse the decision of the NASDAQ Hearings Panel to delist the company from. The company also announced that it has retained Jacob Frenkel, Dickinson Wright, PLLC as its lead counsel in the appeal. According to the announcement, PaxMedica believes the hearings panel did not sufficiently or appropriately consider crucial aspects of the company’s recent achievements and ongoing actions to regain compliance. “We are seeking a reevaluation…

Continue Reading

WednesdayMay 15, 2024 8:30 am

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Releases Q2 Financial Report

NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, has filed on its second-quarter 2024 financial results for the period ending March 31, 2024; the company filed the report with the U.S. Securities and Exchange Commission on May 14, 2024. Notable numbers from the report include cash and cash equivalent totaling $3.51 million, with additional agreements adding approximately $2.5 million more in available cash with property, equipment and intangible assets reported at approximately $7.92 million. The report also noted that the company has a clinical asset in NV-387 that is available for partnering, which could result in a…

Continue Reading

TuesdayMay 14, 2024 4:10 pm

BioMedNewsBreaks — Rejuvine Life Sciences Launches Crowdfunding Campaign

Rejuvine Life, dedicated to developing natural healthcare solutions, today announced a crowdfunding campaign to expand its U.S. product line and advance diabetes research management. According to the announcement, the company utilizes natural resources to support the millions worldwide living with diabetes. Skordo Plus, Rejuvine Life’s leading product, is a garlic-based supplement designed to help regulate blood sugar levels and enhance overall well-being. “We believe everyone deserves access to safe and effective healthcare solutions,” said Pat Theenathayalan, CEO of Rejuvine Life Sciences. “This crowdfunding campaign is a chance for individuals passionate about health to join us in making a significant impact…

Continue Reading

TuesdayMay 14, 2024 3:24 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation Schedule for Upcoming May Conferences

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced that it will participate in three investor conferences in May. Clene will participate in one-on-one meetings at the Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference. See the announcement for more information, including dates and locations of the events. To view the full press release, visit https://ibn.fm/P7S2v About Clene Inc. Clene (along with its…

Continue Reading

TuesdayMay 14, 2024 3:12 pm

BioMedNewsBreaks – Scorpius Holdings Inc. (NYSE American: SCPX) Announces Pricing of Underwritten Public Offering

Scorpius (NYSE American: SCPX), an integrated contract development and manufacturing organization (“CDMO”), has announced the pricing of its underwritten public offering of 60,000,000 common units and/or pre-funded units in lieu thereof. Each common (or pre-funded) unit is being offered at a public offering price of $0.10 (inclusive of the pre-funded warrant exercise price) and consists of one share of common stock (or pre-funded warrant to purchase one share of common stock in lieu thereof) and a common warrant to purchase one share of common stock. The common warrants will have an exercise price of $0.12 per share and will be…

Continue Reading